ECTRIMS 2021
ECTRIMS 2021: A Focus on NMOSD eBOOK
Focus on NMOSD
Read MoreWhat causes NMOSD? Clues from a Canadian Cohort
Disease risk factors and the underlying etiology for neuromyelitis optica spectrum disorder (NMOSD) are not known. Using controls and the validated questionnaire from the Environmental Risk Factors in MS Study (EnvIMS) study [1]...
Read More
ECTRIMS 2021: MRI & Clinical Features Discriminate Between MOGAD, AQP4-NMOSD & RR-MS
Magnetic resonance imaging (MRI) and clinical characteristics could differentiate between...
Read MoreCOVID-19 Vaccines Safe in Patients With NMOSD & MOGAD
While COVID-19 vaccines are recommended for people with neuromyelitis optica spectrum disorder (NMOSD) and MOG-antibody-associated disease (MOGAD), they were not specifically tested in this population, and thus, have an unclear...
Read MoreInebilizumab Sustains Efficacy & Safety During 5.5 Years
Investigators reported final safety and efficacy data from the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), in which patients aged 18 and older who had an Expanded Disability Status Scale...
Read MorePlatelet-to-Lymphocyte Ratio Distinguishes MS From NMOSD
Previous studies have examined the platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte (NLR) ratios as biomarkers of inflammation and disease activity in autoimmune diseases. Researchers assessed the ability of these...
Read MoreHigh Healthcare Use & Costs in Patients With NMOSD
Using a propensity score-matching methodology, investigators examined the economic and healthcare burden of neuromyelitis optica spectrum disorder (NMOSD). The study team performed a retrospective analysis of two claims datasets...
Read MoreEffectively Differentiating MS From Antibody-Mediated Conditions
Researchers sought to determine how well brain and spinal cord lesion criteria perform in discerning MS from neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease...
Read MoreECTRIMS 2021: New Data Reinforce Improved Outcomes with Inebilizumab NMOSD
Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity Results from a new analysis of the inebilizumab pivotal Phase 2/3 N-MOmentum trial were presented this year...
Read MoreECTRIMS 2021: Updates on ULTIMATE I & II Phase 3 Trials of Ublituximab
Data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) will be highlighted at the upcoming 37th Congress of the European Committee for Treatment and...
Read MoreECTRIMS 2021: Ponesimod vs Teriflunomide for RRMS
A total of 10 Janssen-sponsored data abstracts on MS research will be presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual congress from October 13 to 15, in Vienna,...
Read MoreePoster Tours at ECTRIMS This Year
Check Out the New Interactive Program ePoster Tours This year’s ECTRIMS we will have 8 poster tours that will highlight the top scored ePoster. All top scored ePoster authors have been contacted. Poster Tour 1 – Clinical:...
Read More37th Congress of ECTRIMS 2021 is Here
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Vienna is the world’s largest annual international conference devoted to basic and clinical research in multiple...
Read MoreECTRIMS 2021: New Data on Only FDA-approved Anti-CD19 Monoclonal Antibody for NMOSD
New data on inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) will be presented at the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021, Oct. 13-15....
Read MoreECTRIMS 2021: Results on Ocrelizumab in MS and Satralizumab in NMOSD
New data on ocrelizumab and satralizumab-mwge will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 13 – 15, 2021. These data include 38...
Read MoreECTRIMS 2021
Coming soon…
Read MoreECTRIMS 2021
Coming soon…
Read MoreECTRIMS 2021
Coming soon…
Read More